The estimated Net Worth of Jolie Siegel is at least $164 Thousand dollars as of 30 August 2023. Ms Siegel owns over 2,250 units of C4 Therapeutics stock worth over $164,082 and over the last 6 years she sold CCCC stock worth over $0.
Ms has made over 5 trades of the C4 Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently she exercised 2,250 units of CCCC stock worth $13,500 on 30 August 2023.
The largest trade she's ever made was exercising 12,500 units of C4 Therapeutics stock on 10 September 2021 worth over $62,250. On average, Ms trades about 2,044 units every 45 days since 2019. As of 30 August 2023 she still owns at least 27,347 units of C4 Therapeutics stock.
You can see the complete history of Ms Siegel stock trades at the bottom of the page.
Jolie M. Siegel J.D. is the Chief Legal Officer at C4 Therapeutics.
Ms D is 44, she's been the Chief Legal Officer of C4 Therapeutics since . There are 4 older and no younger executives at C4 Therapeutics. The oldest executive at C4 Therapeutics, Inc. is Dr. Kenneth C. Anderson M.D., Ph.D., 70, who is the Co-Founder, Independent Director & Member of Scientific Advisory Board.
Jolie's mailing address filed with the SEC is C/O C4 THERAPEUTICS, INC., 490 ARSENAL WAY #120, WATERTOWN, MA, 02472.
Over the last 4 years, insiders at C4 Therapeutics have traded over $12,678,122 worth of C4 Therapeutics stock and bought 27,275 units worth $336,287 . The most active insiders traders include Marc A Cohen, Alain J Cohen, and Elena Prokupets. On average, C4 Therapeutics executives and independent directors trade stock every 17 days with the average trade being worth of $56,874. The most recent stock trade was executed by Andrew Hirsch on 30 August 2023, trading 7,500 units of CCCC stock currently worth $45,000.
C4 Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader that is in preclinical stage targeting IKZF1/3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; and BRAF V600E to treat melanoma, non-small cell lung cancer, colorectal cancer, and other solid malignancies, as well as RET to treat lung cancer, sporadic medullary thyroid cancers, and other solid malignancies. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffman-La Roche Ltd.; Biogen, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
C4 Therapeutics executives and other stock owners filed with the SEC include: